Variation among hospitals in selection of higher-cost, "higher-tech, " implantable cardioverter-defibrillators: Data from the national cardiovascular data registry (NCDR) implantable cardioverter/defibrillator (ICD) registry

American Heart Journal

Volumn 165, Issue 6, 2013, Pages

  Lampert, Rachel ^a   Wang, Yongfei ^a   Curtis, Jeptha P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIAC PATIENT; FEMALE; HEALTH CARE COST; HOSPITAL; HOSPITAL POLICY; HOSPITAL PURCHASING; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; OUTCOME VARIABLE; PHYSICIAN; PRIMARY PREVENTION; PRIORITY JOURNAL; REGISTER; SECONDARY ANALYSIS; SUPRAVENTRICULAR TACHYCARDIA;

EID: 84880055964     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.12.003     Document Type: Article

References (25)

1. Goldberger Z, Lampert R. Implantable cardioverter-defibrillators: Expanding indications and technologies. JAMA 2006;295:809-18.
2. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980;303:322-4.
3. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
4. Medtronic, tachyarrhythmia management, implantable diagnostic, and electrophysiology products: US price list, February 5, 2007.
5. Curtis LH, Al-Khatib SM, Shea AM, et al. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 2007;298: 1517-24.
6. Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 2007;298:1525-32.
7. Farmer SA, Kirkpatrick JN, Heidenreich PA, et al. Ethnic and racial disparities in cardiac resynchronization therapy. Heart Rhythm 2009; 6:325-31.
8. Rathore SS, Frederick PD, Every NR, et al. Racial differences in reperfusion therapy use in patients hospitalized with myocardial infarction: A regional phenomenon. Am Heart J 2005;149:1074-81.
9. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 2007;153:98-104.
10. Hammill SC, Kremers MS, Stevenson LW, et al. Review of the Registry's second year, data collected, and plans to add lead and pediatric ICD procedures. Heart Rhythm 2008;5:1359-63.
11. Curtis JP, Luebbert JJ, Wang Y, et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA 2009;301:1661-70.
12. Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004;110:2591-6.
13. Larsen K, Petersen JH, Budtz-Jorgensen E, et al. Interpreting parameters in the logistic regression model with random effects. Biometrics 2000;56:909-14.
14. Chan PS, Nichol G, Krumholz HM, et al. Hospital variation in time to defibrillation after in-hospital cardiac arrest. Arch Intern Med 2009; 169:1265-73.
15. Thijssen J, Borleffs JW, vanRees JB, et al. Implantable cardioverterdefibrillator longevity under clinical circumstances. Heart Rhythm 2012;9:513-9.
16. Saxon LA, Hayes DL, Gilliam FR, et al. Long-term outcome after ICD and CRT implant and the influence of remote device follow-up: The ALTITUDE survival study. Circulation 2010;122:2359-67.
17. Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Eng J Med 2012;367:2275-83.
18. Pauker SG, Estes NA, Salem DN. Preventing sudden cardiac death: Can we afford the benefit? Ann Intern Med 2005;142:664-6.
19. Shah B, Hernandez AF, Liang L, et al. Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: Data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. J Am Coll Cardiol 2009;53: 416-22.
20. Zuckerman S, Waidmann T, Berenson R, et al. Clarifying sources of geographic differences in Medicare spending. N Eng J Med 2010; 363:54-62.
21. Epstein AM. Geographic variation in Medicare spending. N Eng J Med 2010;363:85-6.
22. Sirovich B, Gallagher PM, Wennberg DE, et al. Discretionary decision making by primary care physicians and the cost of U.S. health care. Health Aff 2008;27:813-23.
23. Daugherty SL, Peterson PN, Wang Y, et al. Use of implantable cardioverter defibrillators for primary prevention in the community: Do women and men equally meet trial enrollment criteria? Am Heart J 2009;158:224-9.
24. Rao SV, Shaw RE, Brindis RG, et al. Patterns and outcomes of drug-eluting coronary stent use in clinical practice. Am Heart J 2006;152:321-6.
25. Steinbrook R. The controversy over Guidant's implantable defibrillators. N Engl J Med 2005;353:221-4. Data Registry